
Actuate Therapeutics Shares Highlights from KOL Event on Positive Topline Elraglusib Phase 2 Data in First-Line ...
- Expert Insights on Clinical Relevance and Scientific Rationale - The replay of the event is available on the Investor Relations section of the Actuate website CHICAGO and FORT WORTH, Texas, June 02, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. ( …